BioLineRx Reports Third Quarter 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to BioLineRx Reports Third Quarter 2015 Financial Results

Maxim Affirms BiolineRx (BLRX) at 'Buy'; BL-8040 Should be Focus for Immune Oncology Segment

November 16, 2015 2:51 PM EST

Maxim affirms BiolineRx (Nasdaq: BLRX) with a Buy rating and $4 price target following Q3 results reported Monday morning.

The firm summarized:

Pipeline Update: BL-8040 phase II data in relapsed/refractory AML (Acute Myeloid Leukemia) showing a 38% composite response rate will be presented at ASH (December 5-8, 2015), and... More

BioLineRx (BLRX) Tops Q3 EPS by 6c

November 16, 2015 8:34 AM EST

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.06 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

... More